Asuragen
在场
Asuragen 的所有者是 Bio-Techne.
是其中之一......
Bio-Techne 是一家在股票代码 TECH (US) 下上市的公司。
他们在：
涉及Bio-Techne的并购和融资。
- Bio-Techne has announced the acquisition of Lunaphore (公布2023六月23号).
高管
查看带有其 8 名主要高管的组织结构图
Asuragen 搜索最多的简介
- Matt Winkler, Chairman of the Board and Chief Scientific Officer
- Deval Lashkari, Director
- David Sargent, Director
高管在Bio-Techne变化
- Judith Klimovsky已作为Director加入公司 (新闻发布的2024五月2号).
创建提醒
跟踪 Asuragen 的高管变动
生物技术
Bio-Techne 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
- Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
生物技术 行业的其他推荐联系人
消息
Asuragen 的最新新闻稿
- LinkedIn Login, Sign in | LinkedIn
- Bio-Techne to highlight novel solutions for cancer and carrier screening at AMP 2024 Annual Meeting & Expo - Asuragen
- Log in or sign up to view
- X. It’s what’s happening
- https://twitter.com/home?status=Bio-Techne%20Receives%20European%20IVDR%20Certification%20for%20Diagnostic%20Test%20To%20Monitor%20Chronic%20Myeloid%20Leukemia%20https%3A%2F%2Fasuragen.com%2Fnews-list%2Fbio-techne-receives-european-ivdr-certification-for-diagnostic-test-to-monitor-chronic-myeloid-leukemia%2F
- LinkedIn Login, Sign in | LinkedIn
- LinkedIn Login, Sign in | LinkedIn
- BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA - Asuragen
- https://twitter.com/home?status=BIO-TECHNE%20RECEIVES%20EUROPEAN%20IVDR%20CERTIFICATION%20FOR%20DIAGNOSTIC%20TEST%20TO%20MONITOR%20CHRONIC%20MYELOID%20LEUKEMIA%20https%3A%2F%2Fasuragen.com%2Fnews-list%2Fbio-techne-receives-european-ivdr-certification-for-diagnostic-test-to-monitor-chronic-myeloid-leukemia%2F
- View more press releases Close
通过电子邮件
